Professor Sarah Fidler is a clinical academic who provides care for people living with HIV. Her main research interest is in the diagnosis, treatment and cure of HIV infection.
et al., 2022, Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies, Nature Communications, Vol:13, ISSN:2041-1723, Pages:1-6
et al., 2022, Women for science & science for women: gaps, challenges and opportunities towards optimizing HIV-1 prevention, Frontiers in Immunology, ISSN:1664-3224
et al., 2022, Antiretroviral Drug Detection in a Community-Randomized Trial of Universal HIV Testing and Treatment: HPTN 071 (PopART)., Open Forum Infect Dis, Vol:9, ISSN:2328-8957
et al., 2022, Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study, The Lancet Hiv, Vol:9, ISSN:2352-3018, Pages:e771-e780
et al., 2022, Viral suppression and self-reported ART adherence after 3 years of universal testing and treatment in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: a cross-sectional analysis., Lancet Hiv, Vol:9, Pages:e751-e759